Business News

Pfizer Expands Cancer Portfolio through $11.4 Billion Acquisition of Array BioPharma

NEW YORK & BOULDER, Colo.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to …

Read More »

OncoSec Partners with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy, TAVO-PLUS and APOLLO Electroporation Generator

SAN DIEGO, and PENNINGTON, N.J., June 17, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park’s intravital microscopy (IVM) and OncoSec’s proprietary …

Read More »

BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab from Celgene

CAMBRIDGE, Mass. and BEIJING, China, June 17, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has entered into a mutual agreement with Celgene Corporation to …

Read More »

GSK Forms Drug Discovery Alliance with University of California CRISPR Researchers

GlaxoSmithKline plc today announced a five-year collaboration with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR). The new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines. …

Read More »

AbCellera and Gilead Enter Infectious Disease Therapeutic Antibody Discovery Collaboration

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a leader in therapeutic antibody discovery from natural immune systems, today announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases. AbCellera will apply its expertise in single-cell screening of natural immune sources to generate …

Read More »

Sobi Acquires Novimmune Rare Disease Drug Emapalumab and Related Assets

STOCKHOLM, June 12, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced …

Read More »

Synlogic and Ginkgo Bioworks Enter Platform Collaboration for Accelerated Development of Novel Synthetic Biotic Medicines

CAMBRIDGE, Mass. & BOSTON–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform. The agreement provides …

Read More »

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Ingelheim, Germany and Dundee, United Kingdom, 11 June, 2019 – Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins. This brings together the expertise of Professor Alessio Ciulli, one of the …

Read More »

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38

Copenhagen, Denmark; June 11, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a next-generation human CD38 monoclonal antibody product incorporating Genmab’s proprietary HexaBody technology. Under the terms of the …

Read More »

Merck to Acquire Tilos Pharmaceuticals for up to $773 Million, Gaining Portfolio of Investigational Antibodies Modulating TGFβ

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. “At …

Read More »